Image Enhanced Endoscopy IBD

Not Applicable

Recruiting

• Conditions: Inflammatory Bowel Diseases; Dysplasia

• Registration Number: NCT06266104
• Lead Sponsor: Royal Perth Hospital

Brief Summary

Dye- spray chromoendoscopy remains the recommended gold standard approach for IBD dysplasia surveillance colonoscopy however recently published European and American guidelines recommend either dye-spray or virtual chromoendoscopy can be used for surveillance. The newer Imaged Enhanced Endoscopy technologies TXI and LCI have not formally been evaluated in IBD surveillance in a randomised controlled trial setting. These modes can easily be applied during colonoscopy and if demonstrated to be effective may save time and eliminate the need for dye-spray chromoendoscopy in the future.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-02-04
• Study First Submitted QC: 2024-02-10
• Study First Posted: 2024-02-20
• Status Verified: 2024-04
• Study Start: 2024-04-03
• Last Update Submitted: 2024-04-10
• Last Update Posted: 2024-04-12
• Primary Completion: 2025-12-31
• Study Completion: 2026-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 270

Inclusion Criteria

• Patients with inflammatory bowel disease aged 18 to 75 years, that meet Australian recommendations to undergo surveillance colonoscopy will be identified and invited participate in the study.

Exclusion Criteria

• Any active disease
• Inadequate bowel preparation
• Previous surgical resection involving the colon
• History of bowel cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Dysplasia Detection Rate	2 years	Overall Dysplasia Detection rate

Secondary Outcome Measures

Name	Time	Method
Characterisation of lesions	2 years	Accurate characterisation compared to histology
Withdrawal times	2 years	Withdrawal time for procedure

Trial Locations

Locations (1)

Royal Perth Hosptial; 🇦🇺 Perth, Western Australia, Australia